Bertis to Participate in BIO KOREA 2025, 

Showcasing Panomics Analysis Service & Solution ‘PASS’

- Highlights recent research achievements using PASS, including exosome and PROTAC-based therapeutic studies

- Offers customized analysis consultations for drug discovery and basic research in the biopharmaceutical field

On May 2nd, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced its participation in BIO KOREA 2025, taking place at COEX, Seoul, from May 7 to 9. At the event, Bertis will operate a promotional booth to showcase its mass spectrometry-based omics analysis service, PASS (Pan-omics Analysis Service & Solution).

Celebrating its 20th anniversary this year, BIO KOREA is Korea’s largest biohealth exhibition and conference, co-hosted by the Korea Health Industry Development Institute (KHIDI) and Chungcheongbuk-do Province. The event serves as a platform for global healthcare professionals to share the latest industry trends and explore international collaboration and business opportunities. During the exhibition, Bertis will offer on-site consultations to domestic and international researchers and R&D professionals, introducing the customized analytical services and bioinformatics solutions provided by PASS.

PASS is an integrated omics analysis solution that combines advanced mass spectrometry-based proteomics with bioinformatics expertise, supporting diverse needs in pharmaceutical and biotech research, including drug discovery and early-stage development. PASS has recently gained recognition for its data quality and customized consulting capabilities through successful project outcomes, including publication in top-tier journals and regulatory approvals. Notably, a study on acute liver failure using exosome therapeutics was published in Nature Communications in February, and a PROTAC (PROteolysis-Targeting Chimera)-based study for promoting bone regeneration was featured in Advanced Science in March. In April, exosome-based acute ischemic stroke therapy developed by S&E Bio—supported by protein characterization and quality assessment through PASS—received Korea’s first IND approval for a clinical trial in this therapeutic area.

Seong-jun Park, Director of the PASS Center at Bertis, stated, “Through our participation in BIO KOREA 2025, we look forward to sharing our analytical capabilities and recent project achievements with domestic and international stakeholders in basic and translational research. We will continue enhancing our technologies and consulting expertise to serve as a reliable partner in the biopharmaceutical industry.”

Bertis will provide in-depth consultations regarding the PASS service at Booth F19 in Hall C of COEX.